Richard Colvin
Chief Tech/Sci/R&D Officer chez BLUEBIRD BIO, INC.
Fortune : 151 511 $ au 31/03/2024
Profil
Richard Colvin is currently the Chief Medical Officer at bluebird bio, Inc. He previously worked as an Executive Director-Translational Medicine at Novartis, Inc. Dr. Colvin completed his undergraduate degree at Cornell University and obtained a doctorate from Duke University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BLUEBIRD BIO, INC.
0,06% | 01/03/2024 | 118 368 ( 0,06% ) | 151 511 $ | 31/03/2024 |
Postes actifs de Richard Colvin
| Sociétés | Poste | Début |
|---|---|---|
| BLUEBIRD BIO, INC. | Chief Tech/Sci/R&D Officer | 01/03/2021 |
Anciens postes connus de Richard Colvin
| Sociétés | Poste | Fin |
|---|---|---|
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a private company based in San Francisco. | Corporate Officer/Principal | - |
Formation de Richard Colvin
| Cornell University | Undergraduate Degree |
| Duke University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a private company based in San Francisco. | Health Technology |
